Galapagos NV Transfers Predictive Drug Discovery Databases to EMBL's European Bioinformatics Institute

MECHELEN, BELGIUM--(Marketwire - July 23, 2008) - Galapagos NV (Euronext: GLPG) announces the transfer of its databases for predictive drug discovery to the EMBL's European Bioinformatics Institute (EMBL-EBI). The data, which were offered previously through Galapagos' BioFocus DPI service division, will become publicly available on-line to drug discovery researchers worldwide through the EMBL-EBI under license from Galapagos. Galapagos will receive £1.4 million (EUR 1.8 million) in cash. To obtain the rights to the databases, the EMBL-EBI has received funding from the Wellcome Trust, the largest charity in the United Kingdom. The EMBL-EBI will provide access to these data under a grant from the Trust.